EYENOVIA INC (EYEN) Fundamental Analysis & Valuation
NASDAQ:EYEN • US30234E2037
Current stock price
15.82 USD
+5.26 (+49.81%)
At close:
15.9 USD
+0.08 (+0.51%)
After Hours:
This EYEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. EYEN Profitability Analysis
1.1 Basic Checks
- In the past year EYEN has reported negative net income.
- In the past year EYEN has reported a negative cash flow from operations.
- In the past 5 years EYEN always reported negative net income.
- EYEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -708.22%, EYEN is not doing good in the industry: 96.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -708.22% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- EYEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. EYEN Health Analysis
2.1 Basic Checks
- EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, EYEN has more shares outstanding
- Compared to 5 years ago, EYEN has more shares outstanding
- The debt/assets ratio for EYEN is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -62.11, we must say that EYEN is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -62.11, EYEN is not doing good in the industry: 93.30% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -62.11 |
ROIC/WACCN/A
WACC10.96%
2.3 Liquidity
- EYEN has a Current Ratio of 0.34. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
- EYEN's Current ratio of 0.34 is on the low side compared to the rest of the industry. EYEN is outperformed by 94.85% of its industry peers.
- A Quick Ratio of 0.34 indicates that EYEN may have some problems paying its short term obligations.
- EYEN's Quick ratio of 0.34 is on the low side compared to the rest of the industry. EYEN is outperformed by 93.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 |
3. EYEN Growth Analysis
3.1 Past
- EYEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.07%, which is quite impressive.
- EYEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 781.58%.
- EYEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -84.00% yearly.
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%275%
3.2 Future
- EYEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.19% yearly.
- EYEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 135.99% yearly.
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. EYEN Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for EYEN. In the last year negative earnings were reported.
- Also next year EYEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as EYEN's earnings are expected to grow with 20.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.63%
EPS Next 3Y20.36%
5. EYEN Dividend Analysis
5.1 Amount
- EYEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EYEN Fundamentals: All Metrics, Ratios and Statistics
15.82
+5.26 (+49.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-19 2025-05-19/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners9.67%
Inst Owner Change92.79%
Ins Owners0.74%
Ins Owner Change0%
Market Cap80.68M
Revenue(TTM)67.00K
Net Income(TTM)-42.38M
Analysts47.5
Price Target163.2 (931.61%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.5%
Min EPS beat(2)5.64%
Max EPS beat(2)83.35%
EPS beat(4)3
Avg EPS beat(4)17.71%
Min EPS beat(4)-37.25%
Max EPS beat(4)83.35%
EPS beat(8)5
Avg EPS beat(8)6.62%
EPS beat(12)7
Avg EPS beat(12)7.27%
EPS beat(16)10
Avg EPS beat(16)16.18%
Revenue beat(2)0
Avg Revenue beat(2)-96.53%
Min Revenue beat(2)-96.75%
Max Revenue beat(2)-96.32%
Revenue beat(4)0
Avg Revenue beat(4)-97.36%
Min Revenue beat(4)-98.79%
Max Revenue beat(4)-96.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1204.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-34.16
EYN/A
EPS(NY)-26.52
Fwd EYN/A
FCF(TTM)-4.85
FCFYN/A
OCF(TTM)-4.84
OCFYN/A
SpS0.01
BVpS-1.9
TBVpS-1.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -708.22% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 | ||
| Altman-Z | -62.11 |
F-Score3
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)219.51%
Cap/Depr(5y)330.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%275%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%
EBIT growth 1Y-0.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.59%
EBIT Next 3Y54.61%
EBIT Next 5Y39.01%
FCF growth 1Y2.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.27%
OCF growth 3YN/A
OCF growth 5YN/A
EYENOVIA INC / EYEN Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for EYENOVIA INC?
ChartMill assigns a fundamental rating of 1 / 10 to EYEN.
What is the valuation status of EYENOVIA INC (EYEN) stock?
ChartMill assigns a valuation rating of 1 / 10 to EYENOVIA INC (EYEN). This can be considered as Overvalued.
How profitable is EYENOVIA INC (EYEN) stock?
EYENOVIA INC (EYEN) has a profitability rating of 0 / 10.
Can you provide the financial health for EYEN stock?
The financial health rating of EYENOVIA INC (EYEN) is 0 / 10.
Can you provide the expected EPS growth for EYEN stock?
The Earnings per Share (EPS) of EYENOVIA INC (EYEN) is expected to grow by 33.51% in the next year.